Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation

Bone Marrow Transplantation

Volumn 19, Issue 9, 1997, Pages 915-920

  Park, Y D ^a   Yasui, M ^a   Yoshimoto, T ^a   Chayama, K ^a   Shimono, T ^a   Okamura, T ^a   Inoue, M ^a   Yumura Yagi, K ^a   Kawa Ha, K ^a  

^a RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

Author keywords

BMT; Hemostatic parameters; VOD

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 7; COLLAGEN TYPE 3; FIBRINOGEN; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROCOLLAGEN; PROTEIN C; THROMBIN; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADOLESCENT; ARTICLE; BLOOD CLOTTING; BONE MARROW TRANSPLANTATION; CELL DAMAGE; CHILD; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; LIVER VEIN OBSTRUCTION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL;

EID: 0030984716     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700760     Document Type: Article

References (27)

1. Locasciulli A, Bacigalupo A, Alberti A et al. Predictability before transplant of hepatic complications following allogeneic bone marrow transplantation. Transplantation 1989; 48: 68-72.
2. McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 225-245.
3. McDonald GB, Sharma P, Matthews DE et al. The clinical course of 53 patients with veno-occlusive disease of the liver after marrow transplantation. Transplantation 1985; 39: 603-608.
4. Dulley FL, Kanfer EJ, Appelbaum FR et al. Veno-occlusive disease of the liver after chemoradiotherapy and autologous bone marrow transplantation. Transplantation 1987; 42: 870-873.
5. Shulman HM, Gown AM, Nugent DJ. Hepatic veno-occlusive disease after marrow transplantation. Am J Pathol 1987; 127: 540-558.
6. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116-122.
7. McDonald GB, Sharma P, Matthews DE et al. Veno-occlusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116-122.
8. Jones RJ, Lee KSK, Beschorner WF et al. Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778-783.
9. Shulman HM, Hinterberger W. Hepatic veno-occlusive disease-liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 1992; 10: 197-214.
10. Scrobohaci ML, Drouet L, Monem-Mansi A et al. Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers. Thromb Res 1991; 63: 509-519.
11. Gordon B, Haire W, Kessinger A et al. High frequency of antithrombin 3 protein C deficiency following autologous bone marrow transplantation for lymphoma. Bone Marrow Transplant 1991; 8: 497-502.
12. Harper PL, Jarvis J, Jenings I et al. Changes in the natural anticoagulants following bone marrow transplantation. Bone Marrow Transplant 1990; 5: 39-42.
13. Faioni EM, Krachmalnicoff A, Bearman SI et al. Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of veno-occlusive disease of the liver. Blood 1993; 12: 3458-3462.
14. Catani L, Gugliotta L, Belmonte MM et al. Hypercoagulability in patients undergoing autologous or allogeneic BMT for hematological malignancies. Bone Marrow Transplant 1993; 12: 253-259.
15. Rio B, Bauder F, Arrago JP et al. N-terminal peptide of type III procollagen: a marker for the development of hepatic veno-occlusive disease after BMT and a basis for determining the timing of prophylactic heparin. Bone Marrow Transplant 1993; 11: 471-472.
16. Heikinheimo M, Halila R, Fasth A. Serum procollagen type III is an early and sensitive marker for veno-occlusive disease of the liver in children undergoing bone marrow transplantation. Blood 1994; 83: 3036-3040.
17. Seeber C, Hiller E, Holler E et al. Increased levels of tissue plasminogen activator (t-PA) and tissue plasminogen activator inhibitor (PAI) correlate with tissue necrosis factor alpha (TNFα) release in patients suffering from microangiopathy following allogeneic bone marrow transplantation (BMT). Thromb Res 1992; 66: 373-383.
18. Vanhinsbergh VWM, Bauer K, Kooistra K et al. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products. Blood 1990; 76: 2284-2289.
19. Bearman SI, Hinds MS, Wolford JL et al. A pilot study of continuous infusion of heparin for the prevention of hepatic veno-occlusive disease after bone marrow transplantation. Bone Marrow Transplant 1990; 5: 407-411.
20. Attal M, Huguet F, Rubie H et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood 1992; 79: 2834-2840.
21. Bianco JA, Appelbaum FR, Nemunitis J et al. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 1991; 78: 1205-1211.
22. Gluckman E, Jolivet I, Scrobohaci ML et al. Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukemic patients treated by allogeneic bone marrow transplantation. Br J Haematol 1990; 74: 277-281.
23. Essell JH, Thompson JM, Harman GS et al. Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplantation. Bone Marrow Transplant 1992; 10: 367-372.
24. Baglin TP, Harper P, Marcus RE et al. Veno-occlusive disease of the liver complicating ABMT successfully treated with recombinant tissue plasminogen activator (rt-PA). Bone Marrow Transplant 1990; 5: 439-441.
25. Bearman SI, Shuhart MC, Hinds MS et al. Recombinant human tissue plasminogen activator for the treatment of established severe veno-occlusive disease of the liver after bone marrow transplantation. Blood 1992; 80: 2458-2462.
26. Vu LC, Regueira O, Ode DL et al. Recombinant tissue plasminogen activator for veno-occlusive liver disease in pediatric autologous bone marrow transplant patients. Am J Hematol 1994; 46: 194-198.
27. Espigado I, Rodrigues JM, Parody R et al. Reversal of severe hepatic veno-occlusive disease by combined plasma exchange and rt-PA treatment. Bone Marrow Transplant 1995; 16: 313-316.